

# UCB S.A.

ISIN: BE0003739530

WKN: 992418

Asset Class: Stock

<b>Company</b>	2024/05/02 17:35:26
	<b>Price</b> <b>121.85</b> EUR
	<b>Difference</b>  <b>-2.17%(-2.70)</b>



<b>Contact Details</b>	
UCB SA	Tel: +32-2-559-99-99
--	Fax: +
Allée de la Recherche, 60	Web: <a href="http://www.ucb.com">http://www.ucb.com</a>
1070 Brüssel	E-mail: <a href="mailto:contactucb@ucb.com">contactucb@ucb.com</a>

## Company Profile

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	3,444,000,000		3,304,000,000		3,710,000,000	
<b>Common stock capital</b>		584,000,000		584,000,000		584,000,000
<b>Fixed assets</b>	12,095,000,000		12,564,000,000		10,500,000,000	
<b>Equity capital of a company</b>		8,975,000,000		9,064,000,000		8,386,000,000
<b>Cash and cash equivalents</b>	861,000,000		899,000,000		1,263,000,000	
<b>Accrued liabilities</b>		439,000,000		333,000,000		503,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		2,616,000,000		3,112,000,000		2,824,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		3,948,000,000		3,692,000,000		3,000,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		227,000,000		344,000,000		238,000,000
<b>Total assets</b>	15,539,000,000	15,539,000,000	15,868,000,000	15,868,000,000	14,210,000,000	14,210,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	9,083	8,703	8,561
<b>Equity ratio</b>	57.76%	57.12%	59.01%
<b>Debt-equity ratio</b>	73.14%	75.07%	69.45%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	22.22%	17.81%	13.87%

## Income statement

	2023	2022	2021
<b>Turnover</b>	5,252,000,000	5,517,000,000	5,777,000,000
<b>Net income</b>	343,000,000	420,000,000	1,056,000,000
<b>EBIT</b>	558,000,000	578,000,000	1,269,000,000
<b>Operating income before taxes</b>	441,000,000	511,000,000	1,226,000,000
<b>Cash Flow</b>	617,000,000	1,045,000,000	1,490,000,000
<b>Net interest income</b>	-117,000,000	-67,000,000	-43,000,000
<b>Research and development expenses</b>	1,630,000,000	1,670,000,000	1,629,000,000
<b>Income taxes</b>	98,000,000	91,000,000	170,000,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	578,223	633,919	674,804

## Board of Directors

Jonathan Peacock	Chairman of Supervisory Board
Dame Davies	Member of Supervisory Board
Dolca Thomas	Member of Supervisory Board
Jan Berger	Member of Supervisory Board
Susan Gasser	Member of Supervisory Board
Albrecht de Graeve	Member of Supervisory Board
Charles-Antoine Janssen	Member of Supervisory Board
Cyril Janssen	Member of Supervisory Board
Jonkheer Cédric van Rijckevorsel	Member of Supervisory Board
Maëlys Castella	Member of Supervisory Board
Nefertiti Greene	Member of Supervisory Board
Pierre Gurdjian	Member of Supervisory Board
Rodolfo Savitzky	Member of Supervisory Board
Ulf Arne Wiinberg	Member of Supervisory Board

## Members of Management Board

Jean-Christophe Tellier	Chairman of Managing Board
Alistair Henry	Member of Executive Committee
Denelle Waynick Johnson	Member of Executive Committee
Emmanuel Caeymaex	Member of Executive Committee
Fiona du Monceau	Member of Executive Committee
Iris Löw-Friedrich	Member of Executive Committee
Jean Luc Fleurial	Member of Executive Committee
Kirsten Lund-Jurgensen	Member of Executive Committee
Sandrine Dufour	Member of Executive Committee